279P - Genetic polymorphism in the miR-196a as a prognostic biomarker for early breast cancer

Date 29 September 2014
Event ESMO 2014
Session Poster Display session
Topics Translational Research
Breast Cancer
Basic Principles in the Management and Treatment (of cancer)
Presenter Yee Soo Chae
Citation Annals of Oncology (2014) 25 (suppl_4): iv85-iv109. 10.1093/annonc/mdu327
Authors Y.S. Chae1, J.G. Kim1, S.J. Lee1, S. Lee2, B.W. Kang1, W.W. Kim3
  • 1Oncology/hematology, Kyungpook National University Medical Center, 702210 - DAEGU/KR
  • 2Neuclear Medicine, Kyungpook National University Medical Center, 702210 - DAEGU/KR
  • 3Surgery, Kyungpook National University Medical Center, 702210 - DAEGU/KR



As microRNAs (miRNA) may play important roles in tumorigenesis by regulating the expression of proto-oncogenes or tumor suppressor genes, the present study analyzed SNPs located in miRNA and miRNA-binding sites of various genes and their impact on the prognosis for 452 patients with early breast cancer.


Three SNPs (rs3746444, rs11614913, and rs1044129) were selected using in silico analysis and genotyped using the Sequenom MassARRAY.


The median age of all the patients was 48 years, and 283 (62.6%) had ER/PR-positive, 86 (19.0 %) had HER2-overexpressed, and 77 (17.0 %) had triple-negative EBC. During the median follow-up of 6.9 years, 67 (14.8%) relapses and 55 (12.2%) deaths occurred. Among the 3 polymorphisms miR-196a rs11614913T > C was significantly associated with DFS and distant DFS (DDFS) when adjusted for clinical and pathological parameters. In particular, the prognostic impact of rs11614913 was limited to the hormone receptor- expressed subtype, where the patients bearing the CC genotype showed worse survival in terms of RFS and DDFS compared with the patients with the TT or TC genotype as a recessive model (hazard ratio [HR] = 2.610 and P = 0.003 for PFS; HR = 2.730 and P = 0.013 for DDFS).


The current study provides evidence that the miR-196a rs11614913T > C polymorphism is a possible prognostic biomarker for patients with hormone receptor-expressed early breast cancer.


All authors have declared no conflicts of interest.